EA200702278A1 - Антитела, специфичные в отношении tgf-бета 1 - Google Patents
Антитела, специфичные в отношении tgf-бета 1Info
- Publication number
- EA200702278A1 EA200702278A1 EA200702278A EA200702278A EA200702278A1 EA 200702278 A1 EA200702278 A1 EA 200702278A1 EA 200702278 A EA200702278 A EA 200702278A EA 200702278 A EA200702278 A EA 200702278A EA 200702278 A1 EA200702278 A1 EA 200702278A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tgf
- beta
- antibodies specific
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Предлагаются антитела, специфичные для зрелого TGF-бета 1, но не для зрелого TGF-бета 2 и зрелого TGF-бета 3. Антитела характеризуются CDR3 с тяжелой цепью GYRXXXY, где Xпредставляет собой W или А, Х- F или L, Х- Е или Y.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67408205P | 2005-04-22 | 2005-04-22 | |
| PCT/US2006/014943 WO2006116002A2 (en) | 2005-04-22 | 2006-04-20 | Tgf beta 1 specific antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200702278A1 true EA200702278A1 (ru) | 2008-08-29 |
| EA016038B1 EA016038B1 (ru) | 2012-01-30 |
Family
ID=37192643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200702278A EA016038B1 (ru) | 2005-04-22 | 2006-04-20 | Антитело к tgf-бета и его применение |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7619069B2 (ru) |
| EP (1) | EP1874818B1 (ru) |
| JP (1) | JP5070200B2 (ru) |
| KR (1) | KR100978684B1 (ru) |
| CN (1) | CN101163719A (ru) |
| AT (1) | ATE505489T1 (ru) |
| AU (1) | AU2006240056B2 (ru) |
| BR (1) | BRPI0608376A8 (ru) |
| CA (1) | CA2607448C (ru) |
| CY (1) | CY1111518T1 (ru) |
| DE (1) | DE602006021292D1 (ru) |
| DK (1) | DK1874818T3 (ru) |
| EA (1) | EA016038B1 (ru) |
| ES (1) | ES2361269T3 (ru) |
| HR (1) | HRP20110334T1 (ru) |
| IL (1) | IL186775A (ru) |
| NO (1) | NO20076003L (ru) |
| PL (1) | PL1874818T3 (ru) |
| PT (1) | PT1874818E (ru) |
| RS (1) | RS51845B (ru) |
| SI (1) | SI1874818T1 (ru) |
| UA (1) | UA93201C2 (ru) |
| WO (1) | WO2006116002A2 (ru) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009296937B2 (en) * | 2008-09-29 | 2015-02-12 | Centocor Ortho Biotech Inc. | Anti-CD147 antibodies, methods, and uses |
| KR20110097850A (ko) * | 2008-11-22 | 2011-08-31 | 아스튜트 메디컬 인코포레이티드 | 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물 |
| WO2010077831A1 (en) * | 2008-12-16 | 2010-07-08 | Tod Lauerman | Targeted cytokine for treatment of diseases |
| CA3150199A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| EP2688908B1 (en) | 2011-03-23 | 2017-06-21 | Option Pharmaceuticals, LLC | Targeted cytokine for treatment of musculoskeletal diseases |
| ES2894398T3 (es) * | 2011-06-03 | 2022-02-14 | Xoma Technology Ltd | Anticuerpos específicos para TGF-beta |
| SG11201401360XA (en) | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
| CA2866378A1 (en) | 2012-03-08 | 2013-09-12 | Selig Sealing Products, Inc. | Container sealing member with protected security component and removal tab |
| US9518112B2 (en) | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
| MX362456B (es) | 2012-08-24 | 2019-01-18 | Univ California | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| ES2703826T3 (es) * | 2014-02-19 | 2019-03-12 | Merck Patent Gmbh | Inmunoterapia con IL-12 destinada al cáncer |
| CA2973978A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| MX2018010021A (es) | 2016-02-17 | 2018-11-09 | Novartis Ag | Anticuerpos anti tgfbeta 2. |
| US11873340B2 (en) * | 2016-02-26 | 2024-01-16 | The University Of Western Ontario | Anti-CD11D antibodies and uses thereof |
| KR20180122397A (ko) * | 2016-03-11 | 2018-11-12 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
| KR20190007026A (ko) | 2016-05-17 | 2019-01-21 | 제넨테크, 인크. | 면역요법에서의 진단 및 사용을 위한 기질 유전자 특질 |
| SG11201811559WA (en) | 2016-06-27 | 2019-01-30 | Univ California | Cancer treatment combinations |
| WO2018043734A1 (en) * | 2016-09-05 | 2018-03-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-tgf-beta 1 antibodies and methods of use |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| BR112019022873A8 (pt) | 2017-05-02 | 2023-04-11 | Merck Sharp & Dohme | Formulação, e, vaso ou dispositivo de injeção. |
| WO2019045086A1 (ja) * | 2017-08-29 | 2019-03-07 | 林化成株式会社 | 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途 |
| US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
| TW201923089A (zh) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | 癌症之診斷及治療方法 |
| EP3814381A4 (en) | 2018-06-29 | 2022-08-10 | Gensun Biopharma Inc. | TRI-SPECIFIC ANTAGONISTS |
| JP2022504839A (ja) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | 抗ｌａｐ抗体変異体及びその使用 |
| JP2022524281A (ja) | 2019-01-30 | 2022-05-02 | スカラー ロック インコーポレイテッド | ＴＧＦβのＬＴＢＰ複合体特異的阻害剤およびその使用 |
| JP2022540571A (ja) | 2019-06-28 | 2022-09-16 | ゲンスン バイオファーマ、インコーポレーテッド | 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト |
| CN115190812A (zh) | 2020-01-11 | 2022-10-14 | 供石公司 | TGFβ抑制剂及其用途 |
| EP4087659A2 (en) | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| CA3224018A1 (en) * | 2021-06-18 | 2022-12-22 | Genzyme Corporation | Anti-tgf-beta antibody formulations and their use |
| WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| EP1140041A2 (en) * | 1999-01-05 | 2001-10-10 | University of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US7763580B2 (en) * | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| JP2006525362A (ja) * | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| EP1646655A2 (en) * | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
| CA2568336A1 (en) | 2004-06-04 | 2005-12-22 | Genentech, Inc. | Method for treating lupus |
| DK1931709T3 (en) * | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
-
2006
- 2006-04-20 EP EP06750860A patent/EP1874818B1/en active Active
- 2006-04-20 DK DK06750860.6T patent/DK1874818T3/da active
- 2006-04-20 AT AT06750860T patent/ATE505489T1/de active
- 2006-04-20 BR BRPI0608376A patent/BRPI0608376A8/pt not_active IP Right Cessation
- 2006-04-20 CN CNA2006800135110A patent/CN101163719A/zh active Pending
- 2006-04-20 AU AU2006240056A patent/AU2006240056B2/en not_active Ceased
- 2006-04-20 SI SI200631049T patent/SI1874818T1/sl unknown
- 2006-04-20 ES ES06750860T patent/ES2361269T3/es active Active
- 2006-04-20 RS RS20110195A patent/RS51845B/en unknown
- 2006-04-20 JP JP2008507883A patent/JP5070200B2/ja not_active Expired - Fee Related
- 2006-04-20 EA EA200702278A patent/EA016038B1/ru not_active IP Right Cessation
- 2006-04-20 UA UAA200711364A patent/UA93201C2/ru unknown
- 2006-04-20 PT PT06750860T patent/PT1874818E/pt unknown
- 2006-04-20 DE DE602006021292T patent/DE602006021292D1/de active Active
- 2006-04-20 KR KR1020077024149A patent/KR100978684B1/ko not_active IP Right Cessation
- 2006-04-20 WO PCT/US2006/014943 patent/WO2006116002A2/en active Application Filing
- 2006-04-20 CA CA2607448A patent/CA2607448C/en not_active Expired - Fee Related
- 2006-04-20 PL PL06750860T patent/PL1874818T3/pl unknown
-
2007
- 2007-10-18 IL IL186775A patent/IL186775A/en not_active IP Right Cessation
- 2007-10-19 US US11/874,952 patent/US7619069B2/en not_active Expired - Fee Related
- 2007-11-21 NO NO20076003A patent/NO20076003L/no not_active Application Discontinuation
-
2009
- 2009-10-15 US US12/579,447 patent/US8128927B2/en not_active Expired - Fee Related
-
2011
- 2011-05-06 HR HR20110334T patent/HRP20110334T1/hr unknown
- 2011-05-13 CY CY20111100455T patent/CY1111518T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200702278A1 (ru) | Антитела, специфичные в отношении tgf-бета 1 | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| CY2018013I2 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| MY174493A (en) | Binding agents | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| ME00261B (me) | Tweak vezujuća antitijela | |
| EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
| CY1113199T1 (el) | Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης | |
| NO20092052L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
| EA200801414A1 (ru) | Кальцилитические соединения | |
| NO20083593L (no) | Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse | |
| NO20083609L (no) | Fremgangsmater og sammensetninger for malrettet-RELT | |
| TW200716130A (en) | Purified form of tanaproget | |
| MX2007013108A (es) | Reactivos que enlazan ccx-ckr2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY KG MD TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ TJ |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KZ RU |